Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed metastatic renal cell carcinoma
• Bidimensionally measurable disease
• Clear evidence of progression if only site of measurable disease is within previous radiation port
• Previously irradiated brain metastases allowed, if not life threatening, symptoms controlled for 3 months, and not requiring corticosteroids
• PATIENT CHARACTERISTICS:
• Age: 18 and over
• Performance status: ECOG 0-1
• Life expectancy: Greater than 3 months
• WBC at least 3,000/mm3
• Platelet count at least 100,00/mm3
• Bilirubin no greater than 1.5 mg/dL
• Creatinine no greater than 2.0 mg/dL OR creatinine clearance greater than 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception for 1 month before, during, and for 3 months after study
• No active bacterial or viral infection
• No serious underlying medical condition that would interfere with compliance
• No other malignancy within the past 5 years except basal cell carcinoma of the skin
• No dementia or altered mental status that would prevent informed consent
• PRIOR CONCURRENT THERAPY:
• No more than 1 prior therapy with biologic response modifiers
• No prior chemotherapy for advanced disease
• No other concurrent chemotherapy
• No concurrent steriods (except topical use)
• At least 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• At least 4 weeks since major surgery (including nephrectomy)
• No other concurrent experimental agents